{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T17:36:15Z","timestamp":1778002575026,"version":"3.51.4"},"reference-count":93,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.ecl.2022.01.004","type":"journal-article","created":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T10:40:17Z","timestamp":1657276817000},"page":"655-679","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Safety of Statins and Nonstatins for Treatment of Dyslipidemia"],"prefix":"10.1016","volume":"51","author":[{"given":"Connie B.","family":"Newman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ecl.2022.01.004_bib1","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","year":"2010","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.ecl.2022.01.004_bib2","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.ecl.2022.01.004_bib3","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"10.1016\/j.ecl.2022.01.004_bib4","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ecl.2022.01.004_bib5","first-page":"e38","volume":"38","author":"Newman","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"9976","key":"10.1016\/j.ecl.2022.01.004_bib6","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","article-title":"Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials","volume":"385","author":"Cholesterol Treatment Trialists","year":"2015","journal-title":"Lancet"},{"issue":"9753","key":"10.1016\/j.ecl.2022.01.004_bib7","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Cholesterol Treatment Trialists","year":"2010","journal-title":"Lancet"},{"issue":"10170","key":"10.1016\/j.ecl.2022.01.004_bib8","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0140-6736(18)31942-1","article-title":"Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials","volume":"393","author":"Cholesterol Treatment Trialists","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ecl.2022.01.004_bib9","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1159\/000251722","article-title":"Reference values for 27 clinical chemistry tests in 70-year-old males and females","volume":"56","author":"Carlsson","year":"2010","journal-title":"Gerontology"},{"issue":"1","key":"10.1016\/j.ecl.2022.01.004_bib10","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.amjcard.2005.07.108","article-title":"Comparative safety of atorvastatin 80\u00a0mg versus 10\u00a0mg derived from analysis of 49 completed trials in 14,236 patients","volume":"97","author":"Newman","year":"2006","journal-title":"Am J Cardiol"},{"issue":"14","key":"10.1016\/j.ecl.2022.01.004_bib11","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.ecl.2022.01.004_bib12","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","article-title":"SLCO1B1 variants and statin-induced myopathy--a genomewide study","volume":"359","author":"Link","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.ecl.2022.01.004_bib13","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.clpt.2006.09.003","article-title":"Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance","volume":"80","author":"Neuvonen","year":"2006","journal-title":"Clin Pharmacol Ther"},{"issue":"3 Suppl","key":"10.1016\/j.ecl.2022.01.004_bib14","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.jacl.2014.02.010","article-title":"The National Lipid Association\u2019s Safety Task Force. A clinician\u2019s guide to statin drug-drug interactions","volume":"8","author":"Kellick","year":"2014","journal-title":"J\u00a0Clin Lipidol"},{"issue":"5","key":"10.1016\/j.ecl.2022.01.004_bib16","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1080\/17425255.2019.1604685","article-title":"Pharmacokinetics and pharmacodynamics of cytochrome P450 inhibitors for HIV treatment","volume":"15","author":"Gong","year":"2019","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.ecl.2022.01.004_bib17","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1002\/9781119374800.ch45","article-title":"Statin-Related Myopathy and Rhabdomyolysis","author":"Newman","year":"2018","journal-title":"Endocr Metab Med Emergencies"},{"issue":"3","key":"10.1016\/j.ecl.2022.01.004_bib18","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/RHU.0000000000000497","article-title":"Statin-Associated Autoimmune Myopathy: A Systematic Review of 100 Cases","volume":"23","author":"Nazir","year":"2017","journal-title":"J\u00a0Clin Rheumatol"},{"issue":"10","key":"10.1016\/j.ecl.2022.01.004_bib19","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1001\/jama.2015.1335","article-title":"Statin intolerance: Reconciling clinical trials and clinical experience","volume":"313","author":"Newman","year":"2015","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.ecl.2022.01.004_bib20","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1177\/2047487315602861","article-title":"Statin tolerability: In defence of placebo-controlled trials","volume":"23","author":"Tobert","year":"2016","journal-title":"Eur J Prev Cardiol"},{"issue":"4","key":"10.1016\/j.ecl.2022.01.004_bib21","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.jacl.2016.05.002","article-title":"The nocebo effect in the context of statin intolerance","volume":"10","author":"Tobert","year":"2016","journal-title":"J\u00a0Clin Lipidol"},{"issue":"6","key":"10.1016\/j.ecl.2022.01.004_bib22","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1056\/NEJMra1907805","article-title":"Placebo and Nocebo Effects","volume":"382","author":"Colloca","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"10059","key":"10.1016\/j.ecl.2022.01.004_bib23","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ecl.2022.01.004_bib24","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","article-title":"Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial","volume":"9","author":"Moriarty","year":"2015","journal-title":"J\u00a0Clin Lipidol"},{"issue":"15","key":"10.1016\/j.ecl.2022.01.004_bib25","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2016.3608","article-title":"Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: The GAUSS-3 randomized clinical trial","volume":"315","author":"Nissen","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.ecl.2022.01.004_bib26","doi-asserted-by":"crossref","first-page":"301","DOI":"10.7326\/M13-1921","article-title":"N-of-1 (single-patient) trials for statin-related myalgia","volume":"160","author":"Joy","year":"2014","journal-title":"Ann Intern Med"},{"issue":"22","key":"10.1016\/j.ecl.2022.01.004_bib27","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1056\/NEJMc2031173","article-title":"N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side Effects","volume":"383","author":"Wood","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ecl.2022.01.004_bib28","doi-asserted-by":"crossref","first-page":"n135","DOI":"10.1136\/bmj.n135","article-title":"Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials","volume":"372","author":"Herrett","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ecl.2022.01.004_bib29","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.ecl.2022.01.004_bib30","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1001\/jama.2011.860","article-title":"Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: A meta-analysis","volume":"305","author":"Preiss","year":"2011","journal-title":"JAMA"},{"issue":"9841","key":"10.1016\/j.ecl.2022.01.004_bib31","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(12)61190-8","article-title":"Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial","volume":"380","author":"Ridker","year":"2012","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.ecl.2022.01.004_bib32","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/j.jacc.2010.10.047","article-title":"Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials","volume":"57","author":"Waters","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"21","key":"10.1016\/j.ecl.2022.01.004_bib33","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ecl.2022.01.004_bib34","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa061894","article-title":"The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack","volume":"355","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.ecl.2022.01.004_bib35","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1007\/s00125-014-3374-x","article-title":"Statins and glycaemic control in individuals with diabetes: a systematic review and meta-analysis","volume":"57","author":"Erqou","year":"2014","journal-title":"Diabetologia"},{"issue":"9435","key":"10.1016\/j.ecl.2022.01.004_bib36","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.ecl.2022.01.004_bib37","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3132\/dvdr.2008.029","article-title":"The safety and tolerability of atorvastatin 10\u00a0mg in the Collaborative Atorvastatin Diabetes Study (CARDS)","volume":"5","author":"Newman","year":"2008","journal-title":"Diab Vasc Dis Res"},{"issue":"1","key":"10.1016\/j.ecl.2022.01.004_bib38","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s00125-008-1179-5","article-title":"Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes (AFORRD): a randomised controlled trial","volume":"52","author":"Holman","year":"2009","journal-title":"Diabetologia"},{"issue":"9374","key":"10.1016\/j.ecl.2022.01.004_bib39","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(03)13636-7","article-title":"MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial","volume":"361","author":"Collins","year":"2003","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ecl.2022.01.004_bib40","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1001\/jama.2015.1206","article-title":"Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus","volume":"313","author":"Besseling","year":"2015","journal-title":"JAMA"},{"issue":"22","key":"10.1016\/j.ecl.2022.01.004_bib41","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1056\/NEJMoa1604304","article-title":"Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes","volume":"375","author":"Ference","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.ecl.2022.01.004_bib42","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1001\/jama.2016.14568","article-title":"Association Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes: A Meta-analysis","volume":"316","author":"Lotta","year":"2016","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.ecl.2022.01.004_bib43","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1007\/s00125-015-3659-8","article-title":"The loss-of-function PCSK9 p.R46L genetic variant does not alter glucose homeostasis","volume":"58","author":"Bonnefond","year":"2015","journal-title":"Diabetologia"},{"issue":"15","key":"10.1016\/j.ecl.2022.01.004_bib44","doi-asserted-by":"crossref","first-page":"28j","DOI":"10.1016\/0002-9149(88)90004-5","article-title":"Efficacy and long-term adverse effect pattern of lovastatin","volume":"62","author":"Tobert","year":"1988","journal-title":"Am J Cardiol"},{"issue":"1b","key":"10.1016\/j.ecl.2022.01.004_bib45","doi-asserted-by":"crossref","first-page":"25s","DOI":"10.1016\/0002-9343(91)90053-Z","article-title":"Expanded clinical evaluation of lovastatin (EXCEL) study results: IV. Additional perspectives on the tolerability of lovastatin","volume":"91","author":"Dujovne","year":"1991","journal-title":"Am J Med"},{"issue":"2","key":"10.1016\/j.ecl.2022.01.004_bib47","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jhep.2011.07.023","article-title":"Hepatotoxicity associated with statins: Reports of idiosyncratic liver injury post-marketing","volume":"56","author":"Bj\u00f6rnsson","year":"2012","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.ecl.2022.01.004_bib48","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12885-022-09192-1","article-title":"Statin use is associated with the reduction in hepatocellular carcinoma recurrence after liver surgery","volume":"22","author":"Khajeh","year":"2022","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.ecl.2022.01.004_bib49","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1002\/hep.21848","article-title":"Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial","volume":"46","author":"Lewis","year":"2007","journal-title":"Hepatology"},{"issue":"25","key":"10.1016\/j.ecl.2022.01.004_bib50","doi-asserted-by":"crossref","first-page":"7860","DOI":"10.3748\/wjg.v21.i25.7860","article-title":"Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome","volume":"21","author":"Kargiotis","year":"2015","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.1016\/j.ecl.2022.01.004_bib51","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1440-1746.2012.07267.x","article-title":"Combination of fluvastatin with pegylated interferon\/ribavirin therapy reduces viral relapse in chronic hepatitis C infected with HCV genotype 1b","volume":"28","author":"Atsukawa","year":"2013","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.ecl.2022.01.004_bib52","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000354541","article-title":"Impact of added fluvastatin to standard-of-care treatment on sustained virological response in naive chronic hepatitis C Patients infected with genotypes 1 and 3","volume":"57","author":"Selic Kurincic","year":"2014","journal-title":"Intervirology"},{"key":"10.1016\/j.ecl.2022.01.004_bib53","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S1474-4422(09)70058-4","article-title":"Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention","volume":"8","author":"Amarenco","year":"2009","journal-title":"Lancet Neurol"},{"issue":"9","key":"10.1016\/j.ecl.2022.01.004_bib54","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.jacc.2006.07.041","article-title":"Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (Treating to New Targets) study","volume":"48","author":"Waters","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ecl.2022.01.004_bib55","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1212\/01.wnl.0000296277.63350.77","article-title":"Secondary analysis of hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study","volume":"70","author":"Goldstein","year":"2008","journal-title":"Neurology"},{"issue":"21","key":"10.1016\/j.ecl.2022.01.004_bib56","doi-asserted-by":"crossref","first-page":"e468","DOI":"10.1161\/CIR.0000000000000456","article-title":"Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association","volume":"134","author":"Wiggins","year":"2016","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ecl.2022.01.004_bib58","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s12020-018-1541-4","article-title":"Effect of ezetimibe on glycemic control: a systematic review and meta-analysis of randomized controlled trials","volume":"60","author":"Wu","year":"2018","journal-title":"Endocrine"},{"issue":"13","key":"10.1016\/j.ecl.2022.01.004_bib59","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1056\/NEJMsa0806603","article-title":"Analyses of cancer data from three ezetimibe trials","volume":"359","author":"Peto","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"9784","key":"10.1016\/j.ecl.2022.01.004_bib60","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ecl.2022.01.004_bib61","first-page":"385","article-title":"Prospective evaluation of malignancy in 17,708 patients randomized to ezetimibe versus placebo: Analysis from IMPROVE-IT","volume":"2","author":"Giugliano","year":"2020","journal-title":"J\u00a0Am Cardiol CardioOnc"},{"key":"10.1016\/j.ecl.2022.01.004_bib62","unstructured":"Amgen Inc.REPATHA (evolocumab) injection. U.S. Prescribing Information Sept. 2021."},{"key":"10.1016\/j.ecl.2022.01.004_bib63","unstructured":"Sanofi-Aventis U.S. LLC. Praluent (alirocumab) injection. U.S. Prescribing Information Sept. 2021."},{"issue":"7","key":"10.1016\/j.ecl.2022.01.004_bib64","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa1701131","article-title":"Cognitive Function in a Randomized Trial of Evolocumab","volume":"377","author":"Giugliano","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"10106","key":"10.1016\/j.ecl.2022.01.004_bib65","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","article-title":"Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial","volume":"390","author":"Giugliano","year":"2017","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ecl.2022.01.004_bib66","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1161\/CIRCULATIONAHA.120.049447","article-title":"Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of\u00a0Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial","volume":"143","author":"Schwartz","year":"2021","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.ecl.2022.01.004_bib67","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S2213-8587(17)30313-3","article-title":"Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial","volume":"5","author":"Sabatine","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"10.1016\/j.ecl.2022.01.004_bib68","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/S2213-8587(19)30158-5","article-title":"Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial","volume":"7","author":"Ray","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.ecl.2022.01.004_bib69","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S2213-8587(16)30396-5","article-title":"PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study","volume":"5","author":"Schmidt","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.ecl.2022.01.004_bib70","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S2213-8587(16)30398-9","article-title":"PCSK9 inhibition and diabetes: turning to Mendel for clues","volume":"5","author":"Lee","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"16","key":"10.1016\/j.ecl.2022.01.004_bib72","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.ecl.2022.01.004_bib73","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.jacc.2020.12.058","article-title":"Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis","volume":"77","author":"Wright","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ecl.2022.01.004_bib74","unstructured":"Pharmacia and Upjohn Company. Division of Pfizer Inc. Colestid (colestipol hydrochloride tablets). U.S. Prescribing Information May 2017."},{"key":"10.1016\/j.ecl.2022.01.004_bib75","unstructured":"Riaz S, John S. Cholestyramine Resin. StatPearls. Treasure Island (FL)2021."},{"key":"10.1016\/j.ecl.2022.01.004_bib76","unstructured":"Daiichi Sankyo Inc. WELCHOL (colesevelam) tables. U.S. Prescribing Information. October 2021."},{"issue":"12","key":"10.1016\/j.ecl.2022.01.004_bib77","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa674","article-title":"Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline","volume":"105","author":"Newman","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2022.01.004_bib78","unstructured":"Esperion Therapeutics. NEXLETOL (\u2018mpedoic acid). U.S. Product Information Feb 2020."},{"issue":"11","key":"10.1016\/j.ecl.2022.01.004_bib79","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","article-title":"Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol","volume":"380","author":"Ray","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ecl.2022.01.004_bib80","unstructured":"Parke-Davis, Division of Pfizer Inc. LOPID (gemfibrozil). U.S. Prescribing Information Dec 2020."},{"issue":"5","key":"10.1016\/j.ecl.2022.01.004_bib81","first-page":"205","article-title":"Withdrawal of cerivastatin from the world market","volume":"2","author":"Furberg","year":"2001","journal-title":"Curr Control Trials Cardiovasc Med"},{"issue":"17","key":"10.1016\/j.ecl.2022.01.004_bib82","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.ecl.2022.01.004_bib83","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.amjcard.2004.08.076","article-title":"Reporting rate of rhabdomyolysis with fenofibrate\u00a0+ statin versus gemfibrozil\u00a0+ any statin","volume":"95","author":"Jones","year":"2005","journal-title":"Am J Cardiol"},{"issue":"9500","key":"10.1016\/j.ecl.2022.01.004_bib84","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ecl.2022.01.004_bib85","unstructured":"Abb Vie Inc. TRICOR (fenofibrate tablet). U.S. Prescribing Information. March 2021."},{"key":"10.1016\/j.ecl.2022.01.004_bib86","unstructured":"Amarin Pharma Inc. VASCEPA (icosapent ethyl) capsules. U.S. Prescribing Information Dec 2019."},{"key":"10.1016\/j.ecl.2022.01.004_bib87","unstructured":"GlaxoSmithKline. LOVAZA (omega-3-acid ethyl esters capsules). U.S. Prescribing Information Sept 2020."},{"key":"10.1016\/j.ecl.2022.01.004_bib88","unstructured":"AstraZeneca Pharmaceuticals LP. EPANOVA (omega-3-carboxylic acids) capsules. U.S. Prescribing Information March 2017."},{"issue":"22","key":"10.1016\/j.ecl.2022.01.004_bib89","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1001\/jama.2020.22258","article-title":"Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial","volume":"324","author":"Nicholls","year":"2020","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ecl.2022.01.004_bib90","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ecl.2022.01.004_bib91","unstructured":"AMRYT Pharma. JUXTAPID (lomitapide) prescribing information. Dec 2019."},{"issue":"9860","key":"10.1016\/j.ecl.2022.01.004_bib92","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study","volume":"381","author":"Cuchel","year":"2013","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ecl.2022.01.004_bib93","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/jama.284.10.1263","article-title":"Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial","volume":"284","author":"Elam","year":"2000","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.ecl.2022.01.004_bib94","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1136\/heartjnl-2015-308055","article-title":"Niacin therapy and the risk of new-onset diabetes: a meta-analysis of randomised controlled trials","volume":"102","author":"Goldie","year":"2016","journal-title":"Heart"},{"issue":"3","key":"10.1016\/j.ecl.2022.01.004_bib95","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJMc1311039","article-title":"Safety profile of extended-release niacin in the AIM-HIGH trial","volume":"371","author":"Anderson","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.ecl.2022.01.004_bib96","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"Landray","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.ecl.2022.01.004_bib97","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1056\/NEJMe1406410","article-title":"Niacin and HDL cholesterol--time to face facts","volume":"371","author":"Lloyd-Jones","year":"2014","journal-title":"N\u00a0Engl J Med"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852922000044?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852922000044?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:48:28Z","timestamp":1760176108000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852922000044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":93,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S0889852922000044"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2022.01.004","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of Statins and Nonstatins for Treatment of Dyslipidemia","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2022.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}